Kramm, Christof M.

[["dc.bibliographiccitation.journal","Brain Pathology"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","zur Muehlen, Anja"],["dc.contributor.author","Wolff, J."],["dc.contributor.author","Kwiecien, Robert"],["dc.contributor.author","Kramm, C."],["dc.date.accessioned","2018-11-07T09:35:54Z"],["dc.date.available","2018-11-07T09:35:54Z"],["dc.date.issued","2014"],["dc.format.extent","74"],["dc.identifier.isi","000342165800267"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32494"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","18th International Congress of Neuropathology"],["dc.relation.eventlocation","Rio de Janeiro, BRAZIL"],["dc.relation.issn","1750-3639"],["dc.relation.issn","1015-6305"],["dc.title","Histopathological grading according to the WHO classification of CNS tumors and H3.3K27 mutational status represent independent prognostic markers in pediatric high grade gliomas"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","27"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","35"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Pfaff, Elke"],["dc.contributor.author","El Damaty, Ahmed"],["dc.contributor.author","Balasubramanian, Gnana Prakash"],["dc.contributor.author","Blattner-Johnson, Mirjam"],["dc.contributor.author","Worst, Barbara C."],["dc.contributor.author","Stark, Sebastian"],["dc.contributor.author","Witt, Hendrik"],["dc.contributor.author","Pajtler, Kristian W."],["dc.contributor.author","van Tilburg, Cornelis M."],["dc.contributor.author","Witt, Ruth"],["dc.contributor.author","Milde, Till"],["dc.contributor.author","Jakobs, Martin"],["dc.contributor.author","Fiesel, Petra"],["dc.contributor.author","Frühwald, Michael C."],["dc.contributor.author","Hernáiz Driever, Pablo"],["dc.contributor.author","Thomale, Ulrich W."],["dc.contributor.author","Schuhmann, Martin U."],["dc.contributor.author","Metzler, Markus"],["dc.contributor.author","Bochennek, Konrad"],["dc.contributor.author","Simon, Thorsten"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Knirsch, Stephanie"],["dc.contributor.author","Ebinger, Martin"],["dc.contributor.author","von Bueren, André O."],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Herold-Mende, Christel"],["dc.contributor.author","Reuss, David E."],["dc.contributor.author","Kiening, Karl"],["dc.contributor.author","Lichter, Peter"],["dc.contributor.author","Eggert, Angelika"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Pfister, Stefan M."],["dc.contributor.author","Jones, David T.W."],["dc.contributor.author","Bächli, Heidi"],["dc.contributor.author","Witt, Olaf"],["dc.date.accessioned","2020-12-10T14:23:39Z"],["dc.date.available","2020-12-10T14:23:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.ejca.2019.03.019"],["dc.identifier.issn","0959-8049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72003"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","611"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Pediatric Blood & Cancer"],["dc.bibliographiccitation.lastpage","617"],["dc.bibliographiccitation.volume","63"],["dc.contributor.author","Weber, Marie L."],["dc.contributor.author","Schneider, Dominik T."],["dc.contributor.author","Offenmüller, Sonja"],["dc.contributor.author","Kaatsch, Peter"],["dc.contributor.author","Einsiedel, Hagen Graf"],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Claviez, Alexander"],["dc.contributor.author","Ebinger, Martin"],["dc.contributor.author","Kramm, Christof"],["dc.contributor.author","Brecht, Ines B."],["dc.date.accessioned","2021-06-01T10:47:12Z"],["dc.date.available","2021-06-01T10:47:12Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1002/pbc.25839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85519"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","1545-5009"],["dc.title","Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes"],["dc.title.alternative","Pediatric Colorectal Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","64564"],["dc.bibliographiccitation.issue","38"],["dc.bibliographiccitation.journal","Oncotarget"],["dc.bibliographiccitation.lastpage","64578"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","El-Ayadi, Moatasem"],["dc.contributor.author","Ansari, Marc"],["dc.contributor.author","Sturm, Dominik"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","Warmuth-Metz, Monika"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","von Bueren, Andre O."],["dc.date.accessioned","2021-06-01T10:48:31Z"],["dc.date.available","2021-06-01T10:48:31Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.18632/oncotarget.18478"],["dc.identifier.eissn","1949-2553"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17005"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85962"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1949-2553"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","High-grade glioma in very young children: a rare and particular patient population"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","8"],["dc.bibliographiccitation.volume","81"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Krämer, Nadja"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Wiese, Maria"],["dc.contributor.author","Beilken, Andreas"],["dc.contributor.author","Corbacioglu, Selim"],["dc.contributor.author","Dilloo, Dagmar"],["dc.contributor.author","Hernaiz Driever, Pablo"],["dc.contributor.author","Scheurlen, Wolfram"],["dc.contributor.author","Kulozik, Andreas"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","von Bueren, André"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-10-10T07:47:12Z"],["dc.date.available","2018-10-10T07:47:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. We analysed 487 patients from the HIT-HGG database of the German-speaking Society of Pediatric Oncology and Hematology with follow up beyond 1 year. The incidence of SHM was 7.7 ± 3.2% at 10 years. No SHM occurred in 194 patients after first-line TMZ therapy, but four out of 131 patients treated with TMZ for relapse following first-line multiagent chemotherapy experienced SHM (20% at 10 years; p = 0.041). SHMs occurred in two out of 162 patients who underwent multiagent chemotherapy without TMZ (4.1% at 10 years). Gender, patient age and acute haematological toxicity during treatment did not affect the incidence of SHMs. Data of our cohort do not indicate an increased risk of SHM following TMZ treatment when compared to previous chemotherapy regimen. However, if TMZ is administered as a second-line treatment following conventional chemotherapy regimen, the risk might be disproportionately increasing."],["dc.fs.pkfprnr","58469"],["dc.identifier.doi","10.1016/j.ejca.2017.04.023"],["dc.identifier.fs","633320"],["dc.identifier.pmid","28586748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15921"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1879-0852"],["dc.title","Haematological malignancies following temozolomide treatment for paediatric high-grade glioma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1468"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Anti-Cancer Agents in Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","1473"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Kuehnoel, Caspar D."],["dc.contributor.author","Staege, Martin S."],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-11-07T10:19:46Z"],["dc.date.available","2018-11-07T10:19:46Z"],["dc.date.issued","2016"],["dc.description.abstract","Malignant gliomas are tumors with a very unfavorable prognosis. They are characterized by rapid proliferation and invasion in the surrounding healthy tissue. Complete resection of the tumor is still the most important therapeutic option. Despite a variety of therapy modifications in the last years, long term survivors are still rare. Dendritic cell vaccination (DCV) might offer a new therapy option for the treatment of malignant gliomas. Hereby, tumorlysate pulsed dendritic cells (TPDC) can prime T cells to generate anti-tumor immune responses. Lenalidomide is an immune-modulatory piperidine-dione that has demonstrated activity especially in the treatment of hematopoietic malignancies. Here, we tested the combination of DCV and lenalidomide in an in vitro model for immunotherapy of malignant gliomas. No changes of T or NK cell subsets were observed when lenalidomide was used. In addition, interferon gamma enzyme linked immunospot (ELISPOT) showed no effects after priming of autologous peripheral blood mononuclear cells (PBMC) with TPDC and challenge with tumor cells. Although analyses of supernatants did not show higher amounts of interferon gamma and tumor necrosis factor alpha in the presence of lenalidomide, enhanced immune reaction by lenalidomide was detectable by granzyme B ELISPOT. Significantly higher numbers of spots were detected after challenge of TPDC-primed PBMC with tumor cells in the case that lenalidomide was present in the culture medium during priming. Our data suggest that the combination of DCV with lenalidomide might improve immunotherapy for malignant gliomas."],["dc.description.sponsorship","Celgene"],["dc.identifier.doi","10.2174/1871520616666160219131657"],["dc.identifier.isi","000390325500010"],["dc.identifier.pmid","26891975"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41731"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","1875-5992"],["dc.relation.issn","1871-5206"],["dc.title","Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","138"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","143"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Kewitz, Stefanie"],["dc.contributor.author","Stiefel, Martina"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Staege, Martin S."],["dc.date.accessioned","2018-11-07T09:47:07Z"],["dc.date.available","2018-11-07T09:47:07Z"],["dc.date.issued","2014"],["dc.description.abstract","We analyzed the methylation status of the 06-methylguanine-DNAmethyltransferase (MGMT) promoter and mRNA expression in HL cells and assessed the response of these cells to dacarbazine. Expression of MGMT correlated with the presence of non-methylated promoters and cell lines with non-methylated promoters showed increased resistance against dacarbazine. KM-H2 cells expressed fusion transcripts between MGMT and proline-rich coiled-coil 2B (PRRC2B) but no wild type MGMT transcripts. Dacarbazine sensitivity suggested that fusion transcripts are translated into a protein with reduced functionality. MGMT promoter methylation predicts dacarbazine sensitivity of HL cells and it might be interesting to analyze this factor in HL patients. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.leukres.2013.11.001"],["dc.identifier.isi","000329058900021"],["dc.identifier.pmid","24284332"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35037"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0145-2126"],["dc.title","Impact of 06-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1182"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Molecular Imaging & Biology"],["dc.bibliographiccitation.lastpage","1191"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Kewitz-Hempel, Stefanie"],["dc.contributor.author","Kurch, Lars"],["dc.contributor.author","Cepelova, Michaela"],["dc.contributor.author","Volkmer, Ines"],["dc.contributor.author","Sauerbrey, Axel"],["dc.contributor.author","Conrad, Elke"],["dc.contributor.author","Knirsch, Stephanie"],["dc.contributor.author","Pöpperl, Gabriele"],["dc.contributor.author","Steinbach, Daniel"],["dc.contributor.author","Beer, Ambros J."],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Erdlenbruch, Bernhard"],["dc.contributor.author","Reinbold, Wolf-Dieter"],["dc.contributor.author","Odparlik, Andreas"],["dc.contributor.author","Sabri, Osama"],["dc.contributor.author","Kluge, Regine"],["dc.contributor.author","Staege, Martin S."],["dc.date.accessioned","2020-12-10T14:11:58Z"],["dc.date.available","2020-12-10T14:11:58Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s11307-019-01350-5"],["dc.identifier.eissn","1860-2002"],["dc.identifier.issn","1536-1632"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71264"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S234"],["dc.bibliographiccitation.journal","European Journal of Neurology"],["dc.bibliographiccitation.lastpage","S235"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Oenuegoeren, M. Dogan"],["dc.contributor.author","Halve, S."],["dc.contributor.author","Haensch, C. A."],["dc.contributor.author","Isenmann, S."],["dc.contributor.author","Katzenschlager, Regina"],["dc.contributor.author","Kramme, C."],["dc.contributor.author","Lohner, H."],["dc.contributor.author","Monotti, R."],["dc.contributor.author","Schaebitz, W.-R."],["dc.contributor.author","Stoeck, Katharina"],["dc.contributor.author","Strittmatter, Malte"],["dc.contributor.author","Stoegbauer, F."],["dc.contributor.author","Trinka, E."],["dc.contributor.author","von Oertzen, T. J."],["dc.contributor.author","Wiendl, Heinz"],["dc.contributor.author","Woermann, F."],["dc.contributor.author","Bien, Christian G."],["dc.date.accessioned","2018-11-07T09:40:31Z"],["dc.date.available","2018-11-07T09:40:31Z"],["dc.date.issued","2014"],["dc.format.extent","347"],["dc.identifier.isi","000337563600659"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33525"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint Congress of European Neurology"],["dc.relation.eventlocation","Istanbul, TURKEY"],["dc.relation.issn","1468-1331"],["dc.relation.issn","1351-5101"],["dc.title","Comparative case series of GABA(B) and AMPA receptor antibodies associated with limbic encephalitis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","117"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Neuropathologica Communications"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Castel, David"],["dc.contributor.author","Philippe, Cathy"],["dc.contributor.author","Kergrohen, Thomas"],["dc.contributor.author","Sill, Martin"],["dc.contributor.author","Merlevede, Jane"],["dc.contributor.author","Barret, Emilie"],["dc.contributor.author","Puget, Stéphanie"],["dc.contributor.author","Sainte-Rose, Christian"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Jones, Chris"],["dc.contributor.author","Varlet, Pascale"],["dc.contributor.author","Pfister, Stefan M."],["dc.contributor.author","Grill, Jacques"],["dc.contributor.author","Jones, David T. W."],["dc.contributor.author","Debily, Marie-Anne"],["dc.date.accessioned","2019-07-09T11:51:10Z"],["dc.date.available","2019-07-09T11:51:10Z"],["dc.date.issued","2018"],["dc.description.abstract","Diffuse midline glioma (DMG), H3 K27M-mutant, is a new entity in the updated WHO classification grouping together diffuse intrinsic pontine gliomas and infiltrating glial neoplasms of the midline harboring the same canonical mutation at the Lysine 27 of the histones H3 tail.Two hundred and fifteen patients younger than 18 years old with centrally-reviewed pediatric high-grade gliomas (pHGG) were included in this study. Comprehensive transcriptomic (n = 140) and methylation (n = 80) profiling was performed depending on the material available, in order to assess the biological uniqueness of this new entity compared to other midline and hemispheric pHGG.Tumor classification based on gene expression (GE) data highlighted the similarity of K27M DMG independently of their location along the midline. T-distributed Stochastic Neighbor Embedding (tSNE) analysis of methylation profiling confirms the discrimination of DMG from other well defined supratentorial tumor subgroups. Patients with diffuse intrinsic pontine gliomas (DIPG) and thalamic DMG exhibited a similarly poor prognosis (11.1 and 10.8 months median overall survival, respectively). Interestingly, H3.1-K27M and H3.3-K27M primary tumor samples could be distinguished based both on their GE and DNA methylation profiles, suggesting that they might arise from a different precursor or from a different epigenetic reorganization.These differences in DNA methylation profiles were conserved in glioma stem-like cell culture models of DIPG which mimicked their corresponding primary tumor. ChIP-seq profiling of H3K27me3 in these models indicate that H3.3-K27M mutated DIPG stem cells exhibit higher levels of H3K27 trimethylation which are correlated with fewer genes expressed by RNAseq. When considering the global distribution of the H3K27me3 mark, we observed that intergenic regions were more trimethylated in the H3.3-K27M mutated cells compared to the H3.1-K27M mutated ones.H3 K27M-mutant DMG represent a homogenous group of neoplasms compared to other pediatric gliomas that could be further separated based on the type of histone H3 variant mutated and their respective epigenetic landscapes. As these characteristics drive different phenotypes, these findings may have important implication for the design of future trials in these specific types of neoplasms."],["dc.identifier.doi","10.1186/s40478-018-0614-1"],["dc.identifier.pmid","30396367"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16062"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59888"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]